The 96-week trial, published in The Lancet, demonstrated that the drug had no impact on symptoms, brain scans or disease progression in patients with Parkinson’s.
Parkinson’s, a degenerative brain disorder that affects 500,000 Americans, causes symptoms like tremors, stiffness and balance issues, and no treatment has proven effective at slowing its progression. While previous studies suggested GLP-1s might offer a treatment pathway, the large-scale trial failed to show meaningful results.
The setback casts doubt on the potential of GLP-1 drugs, primarily used for weight loss and diabetes, to offer treatments for brain diseases like Alzheimer’s or Parkinson’s.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
